Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
View/ Open
Date
2021-11-01ICR Author
Author
George, DJ
Dearnaley, DP
Type
Journal Article
Metadata
Show full item recordAbstract
Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and increased metabolic and cardiovascular risks. The GnRH antagonist relugolix is able to reduce serum testosterone levels in men with prostate cancer without inducing testosterone flare. In the HERO Phase III trial, relugolix was superior to leuprolide acetate at rapidly reducing testosterone and continuously suppressing testosterone, with faster post-treatment recovery of testosterone levels. Relugolix was associated with a 54% lower incidence of major adverse cardiovascular events than leuprolide acetate. As the first oral GnRH antagonist approved for the treatment of advanced prostate cancer, relugolix offers a new treatment option.
Collections
Subject
Humans
Prostatic Neoplasms
Cardiovascular Diseases
Phenylurea Compounds
Pyrimidinones
Testosterone
Leuprolide
Treatment Outcome
Incidence
Male
Gonadotropin-Releasing Hormone
Randomized Controlled Trials as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Research team
Clinical Academic Radiotherapy (Dearnaley)
Language
eng
Date accepted
2021-08-03
Citation
Future oncology (London, England), 2021, 17 (33), pp. 4431 - 4446
Publisher
FUTURE MEDICINE LTD